Hausen even reported 2 innovative drugs!

On July 28, the CDE official website showed that Hansen Pharmaceuticals continuously applied for two innovative drugs HS-10375 and HS-10381

According to the Insight database, as of July 28, Hansen had 32 products in its innovative drug pipeline

Among them, it is worth noting that in recent years, Hansen has increased its investment in research and development, and the development of innovative drugs has accelerated.

New projects in 2021: immunity, tumor, hypoglycemic

Judging from the disclosed information of Hansen’s newly declared and initiated clinical innovative drug projects in 2021, its new drug layout involves multiple fields, including HS-10360, HS-10374 in the field of self-immunization, anti-tumor drug HS-10365, dual target Point the hypoglycemic drug HS-20094, and the mental field antidepressant HS-10353

Among them, HS-20094 is worthy of attention

Biopharmaceuticals start to work

On July 15th, Hansen Pharmaceutical successively applied for two types of Class 1 therapeutic biological products HS-20093 and HS-20089, which were accepted by CDE, which marked Hansen's start in the field of biological medicine

The first biological drug declared by Hausen is the CD19 monoclonal antibody Inebilizumab introduced from Viela Bio, which is a first-in-class new drug for neuromyelitis optica spectrum disorder (NMOSD)

In addition, Hansen's fastest-growing biologic drug is HS-20090, a biosimilar to Disuzumab, which started phase 1 clinical trials in September 2020

At present, Hansen Pharmaceuticals has established a biological drug research and development center, and its products cover the fields of monoclonal antibodies, double antibodies, ADCs and fusion proteins